<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12490274
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     12
    </month>
    <day>
     19
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2003
    </year>
    <month>
     03
    </month>
    <day>
     27
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1053-2498
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       21
      </volume>
      <issue>
       12
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Dec
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
     </title>
     <isoabbreviation>
      J. Heart Lung Transplant.
     </isoabbreviation>
    </journal>
    <articletitle>
     Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
    </articletitle>
    <pagination>
     <medlinepgn>
      1290-5
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      A substantial proportion of the population with congestive heart failure (CHF) has concomitant airway disease. Little information exists on the tolerability of carvedilol in patients with chronic obstructive pulmonary disease (COPD). In this study, we assessed the tolerability and efficacy of carvedilol in patients with CHF and concomitant COPD or asthma.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Between 1996 and 2000, a total of 487 patients began receiving open-label carvedilol. Forty-three (9%) had COPD (n = 31) or asthma (n = 12). Spirometry supported clinical diagnosis in all, and full pulmonary function testing supported diagnosis in 71%. Sixty percent began carvedilol therapy in the hospital and underwent measurement of peak expiratory flow rates (PEFR) before and after dosing.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      In patients with COPD, mean forced expiratory volume in one second (FEV(1)) was 62% +/- 13% predicted, reversibility was 4% +/- 4% with bronchodilators, and FEV(1)/FVC was 62% +/- 8%. Mean PEFR was 325 +/- 115 liter/min before the dose and increased by 17% 2 hours after the carvedilol dose (p = 0.04). In patients with asthma, mean FEV(1) was 80% +/- 17% predicted, reversibility was 13% +/- 7%, and FEV(1)/FVC was 74% +/- 11%. Mean PEFR was 407 +/- 161 liter/min before the dose with no significant change 2 hours after the dose. Carvedilol was introduced safely in 84% of patients with COPD, with only 1 patient withdrawn from therapy for wheezing. In contrast, only 50% of patients with asthma tolerated carvedilol. Survival at 2.5 years was 72%. In survivors, left ventricular end-diastolic diameter decreased from 76 +/- 11 mm to 72 +/- 14 mm (p = 0.01), left ventricular end-systolic diameter decreased from 65 +/- 13 mm to 60 +/- 15 mm (p = 0.01), and fractional shortening increased from 14% +/- 7% to 17% +/- 7% (p = 0.05) at 12 months.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Patients with CHF and COPD tolerated carvedilol well with no significant reversible airflow limitation, but patients with CHF and asthma tolerated carvedilol poorly. The effect of carvedilol on left ventricular dimensions and function in patients with concomitant airway diseases was similar to that seen in our general group of patients. Asthma remains a contraindication to beta-blockade.
     </abstracttext>
    </abstract>
    <affiliation>
     Cardiopulmonary Transplant Unit, St. Vincent's Hospital, Sydney, New South Wales 2010, Australia.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Kotlyar
      </lastname>
      <forename>
       Eugene
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Keogh
      </lastname>
      <forename>
       Anne M
      </forename>
      <initials>
       AM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Macdonald
      </lastname>
      <forename>
       Peter S
      </forename>
      <initials>
       PS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Arnold
      </lastname>
      <forename>
       Ruth H
      </forename>
      <initials>
       RH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       McCaffrey
      </lastname>
      <forename>
       Dermot J
      </forename>
      <initials>
       DJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Glanville
      </lastname>
      <forename>
       Allan R
      </forename>
      <initials>
       AR
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     J Heart Lung Transplant
    </medlineta>
    <nlmuniqueid>
     9102703
    </nlmuniqueid>
    <issnlinking>
     1053-2498
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Adrenergic beta-Antagonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Carbazoles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Propanolamines
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      72956-09-3
     </registrynumber>
     <nameofsubstance>
      carvedilol
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adrenergic beta-Antagonists
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Asthma
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      epidemiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Carbazoles
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Chi-Square Distribution
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cohort Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Comorbidity
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dose-Response Relationship, Drug
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Follow-Up Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Heart Failure
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="Y">
      epidemiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Maximum Tolerated Dose
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Probability
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Propanolamines
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pulmonary Disease, Chronic Obstructive
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      epidemiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Assessment
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Severity of Illness Index
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Spirometry
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      12
     </month>
     <day>
      20
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2003
     </year>
     <month>
      3
     </month>
     <day>
      28
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      12
     </month>
     <day>
      20
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12490274
    </articleid>
    <articleid idtype="pii">
     S105324980200459X
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

